The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997–2000 |
| |
| Authors: | P J Turner J M Greenhalgh the MYSTIC Study Group |
| |
| Institution: | Antibiotic Development and Technical Support Group, AstraZeneca, Alderley House, Alderley Park, Macclesfield, Cheshire, SK10 4TF, UK;Tel: +44 162 551 5190;Fax: +44 162 551 0725E-mail: |
| |
| Abstract: | In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated from serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997–2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii ; 51 A. calcoaceticus var . lwoffii ; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin–tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms. |
| |
| Keywords: | Antibiotics carbapenems Acinetobacter MYSTIC meropenem |
|
|
